ly-404039
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2012 (NCT01637142)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
GRM3 agonist
Active metabolite of LY2140023
GRM2 agonist
Active metabolite of LY2140023
Chemistry & pharmacology
Loading structure…
SMILES
N[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21- Mol. weight
- 235.22 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL375611 ↗
Also known as
- 4-aminho-2-thiabicyclo(3.1.0)hexane-4,6-dicarboxylic acid
- ly404039
- ly404039
- ly404039
- ly404039
- ly 404039
- ly-404039
- ly-404039
- ly-404039
- ly404040
- ly 404040
- ly-404040
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01637142 | Phase 1 | Jul 1, 2012 | Eli Lilly |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1